Phosphorylation of the Translational Repressor PHAS-I by the Mammalian Target of Rapamycin

Gregory J. Brunn(St. Jude Children's Research Hospital), Christine C. Hudson(St. Jude Children's Research Hospital), Aleksandar Sekulić(St. Jude Children's Research Hospital), Josie M. Williams(St. Jude Children's Research Hospital), Hajime Hosoi(St. Jude Children's Research Hospital), Peter J. Houghton(St. Jude Children's Research Hospital), John C. Lawrence(St. Jude Children's Research Hospital), Robert T. Abraham(St. Jude Children's Research Hospital)
Science
July 4, 1997
Cited by 960

Abstract

The immunosuppressant rapamycin interferes with G1-phase progression in lymphoid and other cell types by inhibiting the function of the mammalian target of rapamycin (mTOR). mTOR was determined to be a terminal kinase in a signaling pathway that couples mitogenic stimulation to the phosphorylation of the eukaryotic initiation factor (eIF)-4E-binding protein, PHAS-I. The rapamycin-sensitive protein kinase activity of mTOR was required for phosphorylation of PHAS-I in insulin-stimulated human embryonic kidney cells. mTOR phosphorylated PHAS-I on serine and threonine residues in vitro, and these modifications inhibited the binding of PHAS-I to eIF-4E. These studies define a role for mTOR in translational control and offer further insights into the mechanism whereby rapamycin inhibits G1-phase progression in mammalian cells.


Related Papers

No related papers found

Powered by citation graph analysis